Methotrexate in advanced bladder cancer

Over a period of 9 years (1970 to 1979), 64 patients with advanced local or metastatic bladder cancer were treated with methotrexate by one of three regimens. Response rates of 50% and over were noted with two of the three regimens studied. The response rate was greater for metastatic disease (44%) than for local disease (16%). Toxicity at the dosage used was minimal provided renal function was satisfactory.